PLx Pharma Inc.

80 articles about PLx Pharma Inc.

• PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

  4/12/2023

  PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.

• PLx Pharma Inc. Receives Nasdaq Delisting Notice - April 11, 2023

  4/11/2023

  PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

  11/10/2022

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

  10/26/2022

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

  8/12/2022

  PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update.

• PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update

  7/27/2022

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022

  6/1/2022

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

  5/20/2022

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

  5/13/2022

  PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update

  4/22/2022

  PLx Pharma Inc. today announced that it will release its 2022 first quarter financial results before the opening of the U.S. financial markets on Friday, May 13, 2022.

• PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

  3/11/2022

  PLx Pharma Inc announced today certain financial and operational results for the three and 12 months ended December 31, 2021.

• PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022

  3/1/2022

  PLx Pharma Inc. today announced that Natasha Giordano, President and CEO of PLx Pharma Inc. and Rita O’Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on March 15, 2022, at Oppenheimer & Co’s 32nd Annual Healthcare Conference, which will be a virtual event this year.

• PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update

  2/22/2022

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

  1/19/2022

  PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

  11/22/2021

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update

  11/12/2021

  PLx Pharma Inc. announced today certain financial and operational results for the three and nine months ended September 30, 2021.

• PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules

  11/4/2021

  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuardTM drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. to Discuss 2021 Third Quarter Financial Results on November 12, 2021 Conference Call and Provide Business Update

  11/1/2021

  PLx Pharma Inc., is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma Inc. Provides VAZALORE Launch Update

  10/29/2021

  PLx Pharma Inc., is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

• PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease

  10/14/2021

  PLx Pharma Inc. today issued a statement on recent United States Preventive Services Task Force (“USPTF”) recommendations on aspirin therapy for primary prevention of cardiovascular disease.